Changing prevalence of darunavir resistance-associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003-2009
نویسندگان
چکیده
Methods Annual prevalence of the IAS-USA 2009 DRV RAMs (V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, and L89V) was studied in approximately 232,000 routine clinical samples submitted to Virco for resistance testing between Jan 2003 and Dec 2009. Prevalence was assessed over time for individual DRV RAMs, DRV RAM combinations and presence of 0, 1, 2, or ≥3 DRV RAMs. Results for DRV RAMs were expressed as the proportion of (1) all clinical samples, (2) samples with evidence of PI resistance (defined by FDA mutation list, or a predicted fold change (FC) in IC50 for any PI greater than the respective virco®TYPE HIV-1 (VTY) lower clinical cut-off [CCO] (FC=10) and (3) samples with DRV resistance defined by predicted FC >10.
منابع مشابه
The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.
BACKGROUND We examined the prevalence of ritonavir-boosted darunavir (DRV) resistance-associated mutations (RAMs) in HIV-infected children in the UK to determine the drug's potential clinical utility as a first-line or second-line protease inhibitor (PI). METHODS The prevalence of DRV RAMs, identified from IAS 2010 and Stanford, and the Stanford susceptibility score, were estimated in PI-naiv...
متن کاملProtease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK
INTRODUCTION Darunavir (DRV) is a preferred agent in treatment guidelines for ART-naïve and experienced patients [1]. It is considered to have a high genetic barrier to resistance and 11 resistance-associated mutations (RAMs) are recognized by IAS-USA [2]. These have largely been identified by analyses examining the correlation between baseline genotype and virological response [3]. However, th...
متن کاملPrevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment.
Eleven protease mutations have been associated with reduced susceptibility to darunavir (DRV). We examined the prevalence and covariates of these mutations in 2 populations. Thirty percent of 1175 Northern California patients and 24% of 2744 non-California patients in the Stanford HIV Drug Resistance Database had viruses with 1 or more mutations associated with resistance to DRV. In multivariat...
متن کاملPrevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil.
Information about resistance profile of darunavir (DRV) is scarce in Brazil. Our objectives were to estimate the prevalence of DRV resistance mutations in patients failing protease inhibitors (PI) and to identify factors associated with having more DRV resistance mutations. All HIV-infected patients failing PI-based regimens with genotyping performed between 2007 and 2008 in a referral teaching...
متن کاملVirological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.
BACKGROUND The aim of this analysis was to characterize viral resistance in the Phase III, randomized ODIN trial, which demonstrated non-inferiority of once-daily darunavir/ritonavir (DRV/r) 800/100 mg to DRV/r 600/100 mg twice daily, each combined with an optimized background regimen in treatment-experienced patients with no DRV resistance-associated mutations (RAMs) at screening. METHODS Vi...
متن کامل